Document is current
Any future updates will be listed below
-
Authors
Vermeulen, Stephanie
Ernst, Sam
Blondeel, Eva
Xia, Zihan
Rappu, Pekka
Heino, Jyrki
Dedeyne, Sándor
Denys, Hannelore
Sys, Gwen
Gijsels, Stefanie
Depypere, Herman
Tummers, Philippe
Ceelen, Wim
Craciun, Ligia
Demetter, Pieter
Raes, Olivier
Hendrix, An
Van der Eycken, Johan
De Wever, Olivier
- License Information
-
More Information
Article History
Received: 23 September 2024
Accepted: 21 November 2024
First Online: 4 December 2024
Declarations
:
: Johan Vander Eycken is patentholder of Pelophen B (PCT/EP2014/075903). All other authors declare no competing interests.
: Informed consent of patients to use tumor material was obtained after the study protocol was approved by the institutional review board of the Ghent University Hospital (EC 2018/0080 and ONZ-2022–0345, EC 2019/1869 and ONZ-2023-0502). All animal experiments were approved by the local ethics committee (ECD 19-45 and ECD 19-86, Ghent University Hospital). All animal experiments were conducted in accordance with the regulatory guidelines of the Ethics Committee of Ghent University Hospital and the ARRIVE guidelines.
